Navigation Links
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Date:6/3/2011

amp;language=English">acute myeloid leukemia (AML). Cornerstone's CPI-613 may represent a potential new alternative treatment for this disease

"I am very excited at the opportunity to present our data from the lab as well as our ongoing phase I trial at ASCO," said Timothy S. Pardee, M.D., Ph.D., lead investigator for the study. "CPI-613 is a very intriguing compound and I hope our studies will lead to improved care for patients who suffer hematologic malignancies."

Pardee will present the data at ASCO June 3-7 in Chicago. The poster session for the study will be on Monday, June 6 from 1 p.m. to 5 p.m. at McCormick Place Hall A. To view the complete abstract of the study (#6590), visit http://abstract.asco.org/AbstView_102_82032.html. More information about clinical trial enrollment is available at http://www.wakehealth.edu.

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and not present in normal cells. Patients with solid tumors and hematologic cancers are currently being enrolled in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have failed all other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages. For further information, visit http://www.cornerstonepharma.com.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a
'/>"/>

SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization of novel ... as primary biliary cirrhosis, today announced that ... Officer, will present at the Deutsche Bank Securities 38th ... on Wednesday, May 29, 2013 at 4:10 p.m. ...
(Date:5/23/2013)...  Inhibikase Therapeutics, Inc., an emerging leader in ... present new results on its antiviral program to ... the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, ... the causative agent of Progressive Multifocal Leukoencephalopathy (PML). ... extended release formulation, can clear JC polyomavirus (JCV) ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Oct. 7 Nile Therapeutics, Inc. (Nasdaq: ... of novel therapeutics for cardiovascular disease, today announced that ... Advisory Board overseeing the development of CD-NP, a dual ... of acute decompensated heart failure. Dr. ...
... Reportlinker.com announces that a new market research report ... RIS/PACS Market http://www.reportlinker.com/p0306627/European-RIS/PACS-Market.html ... terms of the challenges faced by market participants, drivers ... the research service include an executive summary, overview of ...
Cached Medicine Technology:Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 2Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 3Reportlinker Adds European RIS/PACS Market 2Reportlinker Adds European RIS/PACS Market 3
(Date:5/23/2013)... Maintaining its commitment to improving life ... Campaign. Kicking off in the spirit of Better Sleep ... for everyone and to providing a therapeutic sleep experience, ... May is Better Sleep Month, a result of the ... due to the Centers for Disease Control’s confirmation that ...
(Date:5/23/2013)... To kick off barbecue season, fire up the grill this ... with simple tips from Retrofit weight loss . Keep ... , “The powerful heat of the grill can be one ... not mindful of your selections, it can be as bad ... Margulies. , Margulies advises clients to choose healthy options from ...
(Date:5/23/2013)... May 23, 2013 Retül University ... proud to announce the formation of a strategic educational ... Technologies to offer a bike industry first “Positioned ... aerodynamic assessment for time trial, road and triathlon bike ... offered to bike fitters with a Retül University, F.I.S.T. ...
(Date:5/23/2013)... to moderate iodine deficiency during pregnancy may have a ... report. Low levels of the so-called "trace element" ... child at risk of poorer verbal and reading skills ... women can boost their iodine levels by eating enough ... finding, published online May 22 in The Lancet ...
(Date:5/23/2013)... of support for war influences soldier PTSD , ... heightened risk for developing post-traumatic stress disorder if public ... recent research. Social validation or invalidation shapes the level ... the researchers say. The study involved two experiments that ... grinder in one, having an actor show either ...
Breaking Medicine News(10 mins):Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 3Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3Health News:Low Prenatal Iodine May Affect Child's Brain Development 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
... could expose people to serious risks of injury and even death ... ,As lung cancer is the leading cause of cancer deaths among ... could save lives. But a study in New York seems to ... ,Dr. Peter B. Bach, a lung specialist and epidemiologist, who ...
... the number of amyloid plaques in the brains of ... like Alzheimer's. ,Roderic Eckenhoff, MD, Vice Chair ... Anesthesia and Critical Care, and his co-authors, report their ... of Aging. ,Every year over 100 million ...
... grow a genetically modified (GM) variety of rice from ... company behind the proposal, Ventria Bioscience, says the plants ... in infants. ,These plants, incorporating human genes ... some 3,000 acres (1,215 hectares) of farmland in the ...
... intake of soy isoflavones significantly reduced the risk of prostate ... cent//, says a new study. ,"To our knowledge, ... association between isoflavone and localized prostate cancer in Japanese, whose ... Kurahashi from Japan's National Cancer Center. ,Over half ...
... food industry representatives in Sydney has come out with the ... The move follows similar ones followed overseas by other food ... under pressure from the federal government to deal with the ... of trans fats in foods ,to be spelled out on ...
... faster than the current laboratory based detection, which may ... ,Sheila MacNeil and researchers at Sheffield University have ... bacteria in less then a minute by using light, ... ,The technology could have wide applications in wound healing, ...
Cached Medicine News:Health News:CT Scans may Not Benefit Lung Cancer Patients 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: